1. Academic Validation
  2. Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from calophyllum brasiliense that acts by induction of apoptosis

Inhibition of leukemic cell growth by a novel anti-cancer drug (GUT-70) from calophyllum brasiliense that acts by induction of apoptosis

  • Int J Cancer. 2005 Jan 1;113(1):158-65. doi: 10.1002/ijc.20505.
Shinya Kimura 1 Chihiro Ito Naoto Jyoko Hidekazu Segawa Junya Kuroda Masayuki Okada Souichi Adachi Tatsutoshi Nakahata Takeshi Yuasa Valdir Cechinel Filho Hiroshi Furukawa Taira Maekawa
Affiliations

Affiliation

  • 1 Department of Transfusion Medicine and Cell Therapy, Kyoto University Hospital, Kyoto, Japan. shkimu@kuhp.kyoto-u.ac.jp
Abstract

During our search for Cancer chemopreventing compounds derived from plant sources, we discovered that the natural product GUT-70, isolated from the stem bark of Calophyllum brasiliense collected in Brazil, significantly inhibits the growth of leukemic cells. GUT-70, characterized as a tricyclic coumarin, 5-methoxy-2,2-dimethyl-6-(2-methyl-1-oxo-2-butenyl) -10-propyl-2H,8H-benzo[1,2-b;3,4-b']dipyran-8-one (C(23)H(26)O(5)), inhibited all 6 human leukemic cell lines evaluated, including the P-glycoprotein overexpressing cell line, in a concentration and time-dependent manner with IC(50) values from 2-5 microM. Furthermore, GUT-70 did not inhibit colony formation by normal hematopoietic progenitors up to 30 microM and also did not inhibit the proliferation of normal human hepatocytes up to 30 microM. GUT-70 activated the Caspase 2, 3, 8 and 9, and induced the Apoptosis in leukemic cells, which was inhibited by Caspase inhibitors. GUT-70 induced anti-leukemic effects independent of the p53-p2l(WAFl/CIP1) pathway and increased the overall expression of p27(KIP1) and p57(KIP2), to stop the cell cycle at the G(1)/S transition. Thus, a novel anti-cancer drug, GUT-70 isolated from the stem bark of C. brasiliense induces caspase-mediated and p53-independent Apoptosis to overcome multidrug resistance and may become a potent leukemia therapeutics.

Figures
Products